We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer and BioNTech announced that they have dosed the first patients in a global study evaluating their COVID-19 vaccine in pregnant women 18 years and over. Read More
A statistical analysis of multiple clinical trials that assessed Fujifilm’s antiviral Avigan (favipiravir) as a COVID-19 treatment has found that the drug showed limited efficacy in reducing mortality unless given early to infected patients. Read More
The U.S. should postpone second doses of the Pfizer/BioNTech COVID-19 vaccine in order to conserve supply and inoculate as many people as possible, two Canadian researchers recommended, citing data showing the initial dose to be highly effective. Read More
A specially convened UK clinical trial ethics committee has given the go-ahead for a COVID-19 human challenge study that is slated to start within weeks to help inform further vaccine and treatment research. Read More
Efforts to reach large-scale production of a COVID-19 vaccine modified to address new viral variants could take AstraZeneca (AZ) at least six months to achieve, according to company documents. Read More
Roche’s anti-inflammatory drug Actemra (tocilizumab) has been shown to reduce COVID-19-related deaths in the UK’s RECOVERY trial of multiple potential treatments. Read More
The University of Oxford has announced that it has begun the first study of the AstraZeneca (AZ)/Oxford coronavirus vaccine in children and young adults to evaluate if the inoculation is safe and effective in patients aged six to 17. Read More
Patients receiving budesonide also enjoyed a decrease in fever and persistent symptoms, according to the study results posted on the pre-print server medRxiv. Read More
The U.S. has joined the World Health Organization (WHO)’s Access to COVID-19 Tools (ACT) Accelerator program, a global effort to speed development and production of coronavirus vaccines, treatments and tests, and to help lower-income nations obtain them. Read More
The Alzheimer’s Association, which has been lobbying the FDA to approve aducanumab as an Alzheimer’s treatment, claims it had nothing to do with the journal’s action. Read More